Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues
Recent work in the authors laboratory has demonstrated that the repeated injections of high doses of recombinant interleukin 2 (IL 2) can dramatically reduce the number of established pulmonary and hepatic metastases and the growth of intradermal tumors in a variety of murine tumor models. They have thus undertaken studies to define the mechanisms underlying these in vivo effects of IL 2. Using an in vivo DNA-labeling technique in which the authors employed 5-(/sup 125/I)iodo-2'-deoxyuridine (/sup 125/IUdR), they examined the in vivo cell proliferation in the tissues of mice treated with IL 2. A proliferation index (PI) was calculated by dividing the raw counts per minute (cpm) of tissues in IL 2-treated mice by the cpm in corresponding tissues of control animals. At an IL 2 dose of 6000 U given i.p. three times a day, the highest /sup 125/IUdR incorporation was seen in the lungs, liver, spleen, kidneys, and mesenteric lymph nodes (PI = 6.9, 6.9, 5.1, 7.1, 24.6, respectively, at 5 days). The amount of lymphoid proliferation in these organs was a direct function of the dose of IL 2 administered. Other tissues including thymus, intestines, skin, and hind limb showed no significant increase in /sup 125/IUdR uptake even after host treatment with the highest doses of IL 2. Blood and brain demonstrated intermediate incorporation of the radiolabel. Preirradiation of the host largely eliminated the proliferative response to IL 2. Histologic studies of normal and irradiated mice receiving IL 2 corroborated the result of the /sup 125/IUdR findings.
- Research Organization:
- National Cancer Institute, Bethesda, MD
- OSTI ID:
- 5218263
- Journal Information:
- J. Immunol.; (United States), Vol. 2
- Country of Publication:
- United States
- Language:
- English
Similar Records
Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells
Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2
Related Subjects
ANIMAL TISSUES
CELL PROLIFERATION
LYMPHOKINES
BIOLOGICAL EFFECTS
BLOOD
BRAIN
DOSE-RESPONSE RELATIONSHIPS
IN VIVO
INTESTINES
IODINE 125
KIDNEYS
LABELLED COMPOUNDS
LEGS
LIVER
LUNGS
LYMPH NODES
LYMPHOCYTES
METASTASES
MICE
NEOPLASMS
SKIN
SPLEEN
THYMUS
TRACER TECHNIQUES
ANIMAL CELLS
ANIMALS
BETA DECAY RADIOISOTOPES
BIOLOGICAL MATERIALS
BLOOD CELLS
BODY
BODY AREAS
BODY FLUIDS
CENTRAL NERVOUS SYSTEM
CONNECTIVE TISSUE CELLS
DAYS LIVING RADIOISOTOPES
DIGESTIVE SYSTEM
DISEASES
ELECTRON CAPTURE RADIOISOTOPES
GASTROINTESTINAL TRACT
GLANDS
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOTOPE APPLICATIONS
ISOTOPES
LEUKOCYTES
LIMBS
LYMPHATIC SYSTEM
MAMMALS
MATERIALS
NERVOUS SYSTEM
NUCLEI
ODD-EVEN NUCLEI
ORGANS
RADIOISOTOPES
RESPIRATORY SYSTEM
RODENTS
SOMATIC CELLS
TISSUES
VERTEBRATES
551001* - Physiological Systems- Tracer Techniques